Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 7.9% – What’s Next?

Posted by Brenda Bartman on Aug 24th, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report)’s stock price fell 7.9% on Monday . The stock traded as low as $41.25 and last traded at $41.38. Approximately 364,029 shares changed hands during trading, a decline of 84% from the average session volume of 2,269,607 shares. The stock had previously closed at $44.91.

Wall Street Analysts Forecast Growth

DFTX has been the topic of several recent analyst reports. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Needham & Company LLC lifted their target price on Definium Therapeutics from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. JonesTrading increased their price target on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $70.00 price target on shares of Definium Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $63.00.

Read Our Latest Analysis on DFTX

Definium Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The firm has a 50 day moving average price of $42.02 and a 200-day moving average price of $27.88. The company has a market cap of $5.87 billion, a P/E ratio of -12.73 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, research analysts predict that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 48,096 shares of company stock worth $2,165,763 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DFTX. Nykredit A S acquired a new stake in Definium Therapeutics during the second quarter worth $45,000. Caxton Associates LLP bought a new position in Definium Therapeutics during the third quarter valued at about $126,000. Mercer Global Advisors Inc. ADV raised its stake in Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares during the last quarter. BNP Paribas Financial Markets grew its position in Definium Therapeutics by 82.0% in the third quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company’s stock valued at $181,000 after acquiring an additional 6,903 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in Definium Therapeutics by 259.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 13,703 shares of the company’s stock valued at $162,000 after buying an additional 9,886 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.